[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Wingard, 1999 - Google Patents

Fungal infections after bone marrow transplant

Wingard, 1999

View PDF
Document ID
809248186398031426
Author
Wingard J
Publication year
Publication venue
Biology of Blood and Marrow Transplantation

External Links

Snippet

With improved control of cytomegalovirus infection, invasive fungal infections have become the leading cause of infectious mortality after bone marrow transplantation (BMT). A number of changes in transplant practices have led to changes in patterns of fungal infections …
Continue reading at www.tctjournal.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone

Similar Documents

Publication Publication Date Title
Wingard Fungal infections after bone marrow transplant
Loeffler et al. Antifungal drug resistance
Latgé et al. Aspergillus fumigatus and Aspergillosis in 2019
Deresinski et al. Caspofungin
Canuto et al. Antifungal drug resistance to azoles and polyenes
Warnock Fungal infections in neutropenia: current problems and chemotherapeutic control.
Steinbach et al. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis
Park et al. Innate immunity to Aspergillus species
McCormack et al. Caspofungin: a review of its use in the treatment of fungal infections
Kontoyiannis et al. Antifungal drug resistance of pathogenic fungi
Srivastava et al. Emerging virulence, drug resistance and future anti-fungal drugs for Candida pathogens
Wong et al. Dematiaceous molds
Lestner et al. Anidulafungin
Shoham et al. Invasive fungal infections in the ICU
Koh et al. Randomized trial of fluconazole versus low‐dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation
Marr The changing spectrum of candidemia in oncology patients: therapeutic implications
Dodds et al. Antifungal pharmacodynamics: review of the literature and clinical applications
De Pauw et al. Progress in fighting systemic fungal infections in haematological neoplasia
Liu et al. Aspergillus fumigatus escape mechanisms from its harsh survival environments
Boucher et al. Aspergillosis
Ascioglu et al. Prophylaxis and treatment of fungal infections associated with haematological malignancies
Hayes-Lattin et al. Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders
Staber et al. Antifungal management in cancer patients
Banfalvi Improved and adopted murine models to combat pulmonary aspergillosis
Allendoerfer et al. Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis